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The Interaction of Pyridoxal Isonicotinoyl Hydrazone (PIH) and Salicylaldehyde Isonicotinoyl 
Hydrazone (SIH) with Iron. 
 
Yu-Lin Chen1, Xiaole Kong1, Yuanyuan Xie2 and Robert. C. Hider1* 
 
ABSTRACT  
The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl 
hydrazone (SIH), two important biologically active chelators, with iron has been investigated by 
spectrophotometric methods. High iron(III) affinity constants were determined for PIH, logβ2=37.0 and 
SIH, logβ2=37.6. The associated redox potentials of the iron complexes were determined using cyclic 
voltammetry at pH7.4 as +130mV (vs normal hydrogen electrode, NHE) for PIH and +136mV(vs NHE) 
for SIH. These redox potentials are much higher than those corresponding to iron chelators in clinical use, 
namely deferiprone, -620mv; desferasirox, -600mv and desferrioxamine, -468mv. Although the positive 
redox potentials of SIH and PIH are similar to that of EDTA, namely +120mV, the iron complexes of 
these two hydrazone chelators, unlike the iron complex of EDTA, do not redox cycle in the presence of 
vitamin C. These properties render PIH and SIH as excellent scavengers of iron, under biological 
conditions. Both SIH and PIH scavenge mononuclear iron(II) and iron(III) rapidly. These fast kinetic 
properties of the hydrazone-based chelators provide a ready explanation for the adoption of SIH in 
fluorescence-based methods for the quantification of cytosolic iron(II).  
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1. Introduction  
Pyridoxal isonicotinoyl hydrazone (PIH, 1) was initially identified as an iron chelator which possesses 
interesting biological properties in 1979 by Ponka and coworkers 1,2. Subsequent studies demonstrated 
that PIH was effective at scavenging and excreting iron from a range of in vitro and in vivo models 3-8. 
PIH is a tridentate ligand (1) coordinating iron(III) via two oxygen atoms and one nitrogen 9. Its ability to 
scavenge iron from iron-overloaded tissues is related to its relatively low molecular weight, logP value 
and uncharged nature 10, all of which facilitate the entry of PIH into cells. In addition, the 2:1 iron 
complex possesses a favourable logP value and a low charge density and so is able to efflux from cells by 
non-facilitated diffusion”. Preliminary studies in animals and man have demonstrated relatively low 
toxicity 12.  
PIH and many of its analogues possess anti-proliferative activity 13,14,15 and consequently have potential 
in the treatment of cancer 16. Furthermore, this hydrazone family of chelators possess strong antioxidant 
properties 17,18. By virtue of their ability to rapidly enter cells, PIH and salicylaldehyde isonicotinoyl 
hydrazone (SIH) have also been extensively adopted by cell biologists to perturb intracellular iron levels 
19-21. Indeed SIH has found wide application in the calcein-based assay for monitoring the cytosolic labile 
iron pool 22-24. Despite this wide use, there have been few reports of iron affinity constant measurements 
relating to PIH, two with iron(III) 25,26 and one with iron(II) 27. The reported pFe3+ value of 22.9 26 (as 
corrected for [L]Total=10-5M) is similar to that of the tridentate chelators deferasirox (22.5)28 and 
deferitazole (22.3) 29. As with PIH, there are few reports of iron(III) affinity constants for SIH 30. Indeed 
there is some uncertainty regarding the potentiometrically determined affinity constants of both PIH and 
SIH 30. In view of the central importance of these two molecules, we decided to investigate their 
interaction with both iron(III) and iron(II). 
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2. Experimental section 
1H NMR and 13C NMR spectra were measured on a Varian 400(400MHz) spectrometer (chemical shifts 
in δ ppm) using TMS as internal standard. Mass spectra (ESI-MS) were determined on a Thermo Finigan 
LCQ-Advantage. IR Spectra were determined on a Nicolet Avatar-370 spectrometer in KBr (v in cm-1). 
Melting points were measured on a Büchi B-540 capillary melting point apparatus. 
2.1 Materials 
PIH was purchased from Santa Cruz Biotechnology, Heidelberg, Germany. Iron salts, glutathione and 
deferiprone were purchased from Sigma (www.sigmaaldrich.com) 
2.2 Preparation of SIH 
This synthesis utilised the method reported by Hassan et al.19 Isoniazide (4.11g, 30mmol) was dissolved 
in 150mL ethanol at 60oC, then salicylaldehyde (4.03g, 33mmol) was added and the reaction mixture was 
refluxed for 4h. The solution was cooled to 0oC and a yellow precipitate was obtained by filtration. The 
crude product was recrystallized from ethanol to give SIH (6.0g, yield 83%) as pale yellow crystals. 
N’-(2-Hydroxybenzylidene)isonicotinohydrazide  (SIH): Pale yellow solid; m.p. 247.8-248.7oC; IR 
(KBr): νmax = 3438, 3203, 3006, 1684, 1614, 1568, 1291, 772 cm-1; 1H NMR (400 MHz, DMSO-d6) 
δ(ppm): 12.28 (s, 1H, NH), 11.06 (s, 1H, OH), 8.79 (d, 2H, J = 6.0Hz, pyridine-H), 8.67 (s, 1H, N=CH), 
7.84 (dd, 2H, J = 2.0, 4.8 Hz, pyridine-H), 7.60 (dd, 1H, J = 1.6, 7.6 Hz, Ar-H), 7.33-7.29 (m, 1H, Ar-H), 
6.95-6.90 (m, 2H, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ(ppm): 160.9, 157.1, 149.9, 148.9, 139.6, 
131.3, 129.1, 121.2, 119.1, 118.3, 116.2; MS (ESI): m/z (%) = 240; C13H11N3O2, requires C, 64.72%; H, 
4.60% and N, 17.41%; found, C, 64.72%; H, 4.52% and N, 17.47%. 
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2.3 pKa and iron stability constants 
The automated titration system used in this study comprised of an autoburette (Metrohm Dosimat 765 
liter ml syringe) and Mettler Toledo MP230 pH meter with Metrohm pH electrode (6.0133.100) and a 
reference electrode (6.0733.100). 0.1 M KCl electrolyte solution was used to maintain the ionic strength. 
The temperature of the test solutions was maintained in a thermostatic jacketed titration vessel at 25°C ± 
0.1°C by using a Techne TE-8J temperature controller. The solution under investigation was stirred 
vigorously throughout titrations. A Gilson Mini-plus#3 pump with speed capability (20 ml/min) was used 
to circulate the test solution through a Hellem quartz flow cuvette. For the stability constant 
determinations, a 50 mm path length cuvette was used, and for pKa determinations, a cuvette path length 
of 10 mm was used. The flow cuvette was mounted on an HP 8453 UV-visible spectrophotometer. All 
instruments were interfaced to a computer and controlled by a Visual Basic program. Automatic titration 
and spectral scans adopted the following strategy: the pH of a solution was increased by 0.1 pH unit by 
the addition of KOH from the autoburette; when pH readings varied by <0.001 pH unit over a 30 s period, 
they were judged to be stable and the spectrum of the solution was recorded. The cycle was repeated 
automatically until the defined end point pH value was achieved. All the titration data were analyzed 
with the pHab program 32. Species plots were calculated using the HYSS program 33. The values of logK1 
and logβ2, as defined in equations (i) – (iii), were determined by use of the HYSS program 33.  
Analytical grade reagent materials were used in the preparation of all solutions. 
Equations (i) – (iii) here 
In addition to logK1 and logβ2 values, pFe3+ values have been adopted by chelation chemists as a 
convenient means of comparing the iron(III) chelating capability of different ligands at pH 7.4. At this 
pH, there can be appreciable competition for the ligand by protons. In contrast, the logK1 and logβ2 
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values are based on the values for the equilibrium constant in the absence of proton competition 
(equations (i) and (ii)). 
pFe3+ values are determined from logβ values, pKa values, pH and total concentrations of FeIII and ligand. 
Typically, when comparing iron(III) chelators of clinical interest, the following conditions are adopted; 
[Fe3+]Total = 10-6M; [Ligand]Total = 10-5M and pH = 7.4 34. 
2.4 Electrochemical Measurements  
Cyclic voltammetry (CV) measurements were performed with an CS-120 device (Corrtest). Solutions of 
SIH or PIH (2mM) with iron(III) (1mM) at pH 7.42 (0.1M 3-morpholinopropane-1-sulfonic acid, MOPS, 
20% DMSO V/V) were investigated. All measurements were conducted under N2 in a jacketed, 
one-compartment cell with a platinum disk working electrode (geometric area: 0.07 cm2) (Corrtest), a 
platinum wire counter electrode (Corrtest) and a Ag/AgCl reference electrode. The working electrode 
surface was polished, sonicated in water, and air-dried immediately before use. The sweep rate was 100 
mV/s. O2 was removed from the electrolyte solution by bubbling N2 through the solvent for several 
minutes prior to measurement. A N2 atmosphere was continuously maintained above the solution while 
the experiments were in progress. The temperature was controlled by using a double-jacketed cell and a 
thermostat with water bath at 25 oC. 
2.5 Kinetic spectrophotometric measurements 
All kinetic studies were undertaken at pH 7.4 (25mM MOPS) and 25oC. The iron concentration adopted 
throughout was 10μM and the corresponding ligand concentration was chosen based on its dentate 
number, 30μM for deferiprone, 20μM for SIH and PIH. Iron(II) sulphate was used as a source of iron(II) 
and the solutions were prepared immediately before use. Iron(III) nitrate was used as a source of iron(III), 
again the solutions being prepared immediately before use. The usual practice of using iron(III) 
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nitrilotriacetic acid (NTA) solutions was not adopted because NTA interferes with kinetics of iron 
substitution. The glutathione concentration was 2mM. The UV-Visible spectra were recorded by an HP 
8453 UV-visible spectrophotometer with a 50mm Hellem quartz flow cuvette being circulated by a 
Gilson Mini-plus #3 pump – speed capability (20mL/min), controlled by in-house computer software. 
3. Results 
3.1 Determination of pKa values 
PIH was found to be relatively stable over the pH range 1-10, in contrast to SIH which was found to be 
unstable at pH values less than 2 (Figure S1 supplementary data). This is likely to result from the 
hydrolysis of the Schiff base. Thus exposure of this ligand to pH values < 2.0 was avoided during 
titration studies. 
The spectrophotometric analysis of the titrations of PIH and SIH (Figure 1) were fitted to four and three 
pKa values respectively. The corresponding pKa values are given in Table 1. There is good agreement 
with the study of Richardson et al 35 and although we agree with their assignment of pKa values for SIH, 
as indicated in figure 2, we do not agree with the previous assignment of values for PIH. Based on 
studies by Metzler and Snell 36, Richardson assigned their measured pKa value of 4.20 to the phenolic 
function 35. However, titration of 3-hydroxypyridine and its analogue, pyridoxine, follows the sequence 
indicated in equation (iv) 37,38. Based on these studies, we propose the pKa assignments for PIH are as 
indicated in figure 2. These assignments are close to those calculated for PIH by Marvin 39. The influence 
of pH on the speciation plots of the two ligands is presented in figure 3. With both compounds, there is a 
mixture of the non-charged species and the monoanionic species at pH 7.4.  
Equation (iv) here. 
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3.2 Determination of the iron(III) affinity constants 
PIH and iron(III) were titrated in a 2:1 molar ratio against KOH over the pH range 1.3-7.5. There is an 
isosbestic point at 475 nm with the λ max shifting from 473 to 465 nm (Figure S2, supplementary data). 
The data is consistent with the formation of two complexes, namely Fe·(PIH) and Fe·(PIH)2. The affinity 
constants logK1 and logβ2 were determined as 20.3 and 37.0. (Table 1). The speciation plot of the 
iron(III)-PIH system is presented in figure 4A, where the dominant complex at pH 7.4 is [FeIII(PIH)2]-. 
The logβ2 value of 37.0 is larger than the value reported by Vitolo et al 26, namely 30.4. SIH and iron(III) 
were titrated in a 2:1 molar ratio against KOH over the pH range 2.0-5.0 (Figure S3, supplementary 
material). There is an isosbestic point at 665 nm and the data is consistent with the formation of two 
complexes, namely Fe·(SIH) and Fe·(SIH)2. The affinity constants logK1 and logβ2 were determined as 
19.3 and 37.6 which are much lower than those previously reported, namely 38.3 and 56.0 26. The 
speciation plot of the iron(III)-SIH system is presented in figure 4B, where the dominant complex at pH 
7.4 is [FeIII(SIH)2]-. 
3.3 Determination of the oxidation potentials of the iron complexes of PIH and SIH 
Due to the limited solubility of the complexes, cyclic voltammetry was performed at pH 7.45 in the 
presence of 20% DMSO (by volume) with a molar ratio of ligand: iron of 2:1. The solutions were 
buffered with MOPS (0.1M). The voltammograms for PIH/iron behave in a semi-reversible manner 
(Figure 5). The measured electrode potential is +130mV (vs NHE). A similar electrode potential was 
obtained for SIH, namely +136mV (vs NHE). The stability constants for iron(II) were calculated from 
the corresponding iron(III) stability constants and the electrode potential, using a standard 
thermodynamic cycle as Ecomplex(Fe3+/Fe2+) = E(Fe3+/Fe2+) - 59.15*(logβFe3+- logβFe2+). Values of 
logβ2(Fe2+) for PIH and SIH were determined as 26.1 and 26.9 respectively. These values are higher the 
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those previously reported for PIH, namely 12.47 26. 
3.4 Kinetic studies of vitamin C oxidation 
As the redox potential of ascorbate, under physiological conditions, is in the region of +100mV 40, PIH 
and SIH iron complexes are predicted to redox cycle in a similar fashion to that of the iron complexes of 
NTA and EDTA. However, whereas the iron(III) complexes of both these aminocarboxylate ligands 
readily oxidise reduced vitamin C (300μM at pH 7.4) as monitored at 265nm, the iron(III) complexes of 
SIH and PIH do not oxidise vitamin C, behaving like the iron(III) complexes of deferiprone and 
desferrioxamine (Data not presented). In order to confirm this behaviour we coupled vitamin C with 
dichlorophenolindophenol where the coupled dye enabled measurement of the redox process at 700nm, 
(equation (v)) 41. Again, we found that whereas the iron(III) complexes of deferiprone, desferrioxamine, 
SIH and PIH do not oxidise reduced vitamin C, the iron(III) complexes of NTA and EDTA do (Figure 6). 
Equation(v) here 
Thus although the redox potentials of the iron complexes of both SIH and PIH are similar to those of 
NTA and EDTA, they are kinetically much slower. This difference almost certainly results from the 
effective steric blocking by the two chelating ligands, effectively preventing access to the coordinated 
iron(III). In contrast, with the aminocarboxylate iron(III) complexes, there is a vacant coordinative site in 
both iron(III) complexes 42, which are readily accessible to the approach by other ligands and reactants. 
3.5 Kinetic studies of iron complex formation 
The visible spectra of iron(III)(SIH)2, iron(II)(SIH)2, iron(III)(PIH)2 and iron(II)(PIH)2 at pH 7.4 are 
presented in figure 7. With both ligands, the spectra of the iron(II) complexes extends to higher 
wavelengths, with a shoulder for iron(II)(SIH)2 at 550nm and a shoulder for iron(II)(PIH)2 at 490nm 
(Figure 7). PIH and SIH scavenge both iron(II) and iron(III) rapidly at pH 7.4 with no apparent redox 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
9 
 
reaction. Thus both ligands chelate iron(II) (presented as FeSO4) rapidly (complete within 3 min), 
forming the respective iron(II) complexes and with iron(III) (presented as iron(III)(NO3)3), although this 
latter process takes slightly longer to complete, approximately 10 min. (Data not presented). These 
findings confirm that PIH and SIH bind both iron(II) and iron(III) with relatively high affinity. 
The behaviour of both PIH and SIH contrasts markedly with that of deferiprone (3), a 
3-hydroxypyridin-4-one. When deferiprone is incubated with iron(II) at pH 7.4 the iron(III) (deferiprone) 
complex is formed extremely rapidly (< 1min) 43,44 (Figure 8A). Thus as with deferrioxamine, rapid 
autoxidation occurs 45 due to the affinity of deferiprone for iron(II) being much lower than for iron(III) 43. 
Surprisingly however deferiprone scavenges iron(III), when presented as the nitrate salt, much more 
slowly than both SIH and PIH (Figure 8B). Complete chelation of iron(III) at pH 7.4 takes approximately 
30 min. We interpret this difference as resulting from the relatively slow rate of exchange of FeIII-OH 
bonds when compared to FeII-OH bonds 46. This renders the rate of substitution of OH- functions by a 
ligand much slower for iron(III) than iron(II) (equation vi). The position of equilibrium for this reaction 
will be strongly influenced by the value of the K1 affinity constant of the ligands under consideration. 
The logK1 values for SIH and PIH are of the order of 20 (Table 1), whereas the corresponding value for 
deferiprone is 14 47. This offers a clear explanation for differences in the rate of scavenging iron(III) at 
pH 7.4.  
Equation (vi) here 
A knowledge of the rates at which SIH and deferiprone scavenge different forms of iron is important for 
the interpretation of the mode of action of fluorescent probes, when the quenching of the latter is used to 
quantify cytosolic iron(II) levels 48. As iron(II) glutathione is the major species of labile iron in both the 
cytosol and the lumen of the mitochondrion 49.50, it was decided to repeat the above chelation studies with 
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iron(II) in the presence of glutathione (2mM). Again, PIH and SIH were able to scavenge iron from 
FeII-GS, rapidly (complete with 3 min), the redox state of the scavenger iron was iron(III) (Fig 9A). We 
interpret this redox reaction as resulting from the formation of mixed glutathione/SIH complexes 
equation (vii). With deferiprone, iron scavenging is much slower in the presence of glutathione (2mM) 
(Fig 9B) and again this reflects the differences in the logK1 values for iron(III). 
4. Discussion   
4.1 Affinity constants for iron(III) and iron(II) 
As outlined in the introduction, both the hydrazone chelators PIH and SIH have been extensively adopted 
by cell biologists and biomedical scientists because of their high binding affinity for iron. Despite this 
wide use, there is some uncertainty regarding the published affinity constants for both iron(II) and 
iron(III). With the two chelators, depending on the pH, both the 1:1 and 2:1 iron(III) complexes can be 
characterised. The iron(III) logβ2 value determined for PIH in this work, namely 37.0, is somewhat 
higher than that previously reported 25,26. Furthermore, favoring the assignment of the pKa value 4.4 to 
the ring N of the pyridoxine moiety, influences the calculation for the determination of pFe3+ values. The 
value resulting from this work ([Fe3+]total=10-6M, [PIH] total=10-5M, pH7.4）is 26.2, which is lower than the 
previously published value of 27.7 26. However, the previous workers adopted different conditions for 
pFe3+, namely [Fe3+]total=10-6M, [PIH] total=10-3M, pH7.4. Applying these conditions to the data 
determined in this work leads to the higher value of 30.4. As indicated in the Experimental Section, the 
generally accepted conditions for pFe3+ calculations, as applied to clinically useful iron chelators are 
[Fe3+]total=10-6M and [Ligand] total=10-5M, pH 7.4 34. We therefore suggest the pFe3+ value of 26.2 being 
adopted for PIH. (Table 1) 
The iron(III) logβ2 value for SIH, as determined in this work, is similar to that of PIH, namely 37.6, 
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which corresponds to a pFe3+ value of 24.6. These two values would appear to be appropriate for 
tridentate iron(III) selective chelators (Table 2), the value for PIH falling at the higher end of the range 
for tridentate ligands. Indeed, these values are greater than the pFe3+ values generally assessed to be 
suitable for scavenging iron in biological matrices (i.e. pFe3+ ≥ 20) 51. 
We found that the two hydrazone iron complexes possess higher redox potentials than the three iron 
chelators in current clinical use, namely desferoxamine, -468mV; deferasirox, -600mV; deferiprone, 
-620mV, respectively 52,53. This difference in properties is associated with the two hydrazone chelators 
possessing an appreciable affinity for iron(II) 51 (Table 1). The positive redox potentials of SIH, +136mV, 
and PIH, +130mV, are similar to that of EDTA, namely +120mV 17. Therefore, the iron complex of these 
two hydrazone chelators, like the iron complex of EDTA, might be expected to redox cycle, via the 
Fenton reaction, under physiological conditions 17. However, this is not the case, as demonstrated in 
figure 6, where both the hydrazone chelators failed to trigger appreciable vitamin C oxidation. This 
finding offers a clear explanation for the antioxidant protective effect of PIH in the presence of both 
FeNTA and FeEDTA 17,18 and probably is a result of the two coordinating ligands providing sufficient 
steric hindrance to minimise access of reagents to the coordinated iron atom. 
4.2 Kinetics of iron(II) and iron(III) complex formation 
As discussed by other workers, PIH and SIH scavenge labile iron rapidly 20,21,54 and both the iron(II) and 
iron(III) complexes are kinetically stable, presumably due to the formation of tight octahedral complexes 
which are resistant to ligand substitution. 
In the presence of physiological levels of glutathione, iron(II) is scavenged by PIH and SIH as iron(III) 
and in many ways behaves in a similar fashion to deferiprone. This finding has important implications 
for the quantification of cytosolic labile iron by the use of fluorescence probes, as the relevant iron 
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affinity constants must be used in the calculations 20,55.  
Abbreviations 
PIH  Pyridoxal isonicotinoyl hydrazone 
SIH  Salicylaldehyde isonicotinoyl hydrazone 
MOPS 3-(N-Morpholino)propanesulfonic acid 
NHE Normal hydrogen electrode 
NTA Nitrilotriacetic acid 
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Figure 1. Spectrophotometric titration of A, [PIH]= 40uM. pH 2.049 to 11.064 and B, [SIH]= 51.8uM. pH 
2.37 to 11.38. 
Figure 2. Assignment of pKa values in PIH (1) and SIH (2). Structure of deferiprone (3). 
Figure 3. Speciation plots of the ligands over the pH range 0-12; A, PIH and B, SIH. 
Figure 4. A, Speciation plot of Fe(III)/PIH under conditions: [PIH], 80uM; [Fe3+], 40uM, and B, speciation 
plot of Fe(III)/SIH under conditions: [SIH], 80uM; [Fe3+], 40uM. 
Figure 5. A. Cyclic voltammetry scan of PIH:Fe (2:1), [Fe] = 2mM at pH 7.45 (0.1M, MOPS; 20% v/v 
DMSO); B. Cyclic voltammetry scan of SIH:Fe (2:1), [Fe] = 2mM at pH 7.45 (0.1M, MOPS; 20% 
v/v DMSO). The measurements were performed between +450 to -500mV with the sweep rate of 
100mV/s for 3 to 5 cycles. 
Figure 6. Oxidation of vitamin C as monitored by the oxidation of dichlorophenolindophenol; [Fe3+], 10 μM; 
◆EDTA, 10 μM; (blue), NTA, 20 μM; ■, deferiprone, 30 μM; ▲,SIH. 20 μM; (purple), PIH, 
20 μM; ●, DFO, 10 μM. 
Figure 7. Spectra of PIH (A) and SIH (B); 400-800 nm [iron], 10 μM; [Ligand] 20 μM, pH 7.4 (MOPS, 20 
mM). L, ——; LFe2+ ∙∙∙∙∙∙∙∙∙; LFe3+ – – – –. 
Figure 8. Chelation of iron by deferiprone [iron], 10 μM, [deferiprone], 30 μM. Spectra recorded every 2 
minutes, A, with iron(II) sulphate; B, with iron(III) nitrate. 
Figure 9. Competition between iron(II) glutathione and various ligands. Monitored by spectroscopy (400 – 
800 nm). Spectra recorded every two minutes. [Fe2+], 10 μM; [GSH], 2 mM; A, PIH, 20 μM; B, SIH, 
20 μM; C, deferiprone, 30 μM. 
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Table 1 pKa values and iron(III) affinities and oxidation potentials*. 
 pKa Fe3+ 
Oxidation  
potential(NHE)*** 
 
 SIH 
10.9 
8.0 
3.1 
logK1=19.3 
logβ2=37.6 
pFe3+=24.6** 
+136mV 
PIH 
10.3 
7.5 
4.5 
2.3 
logK1 = 20.3 
logβ2 = 37.0 
pFe3+=26.2** 
+130mV 
*Repeated experiments can result in about 1% deviation for stability constant values. 
**pFe3+ under the conditions of [ligand]Total = 10-5M, [Fe3+]Total = 10-6 M, pH 7.4 
***By cyclic voltammetry at pH 7.45 MOPS buffer (0.1M)(20%V/V DMSO). 
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Table 2 Chelator class and pFe3+ values 
Chelator Chelator 
class 
Stoichiometry of 
dominant complex  
at pH7 
pFe3+ 
Maltol Bidentate 3:1 15 
N,N-Dimethyl-2,3-dihydroxybenzamide Bidentate 2:1 15 
Deferiprone Bidentate 3:1 20.4 
    
Deferasirox Tridentate 2:1 22.5 
Deferitazole Tridentate 2:1 22.3 
SIH Tridentate 2:1 24.6 
PIH Tridentate 2:1 26.2 
    
DFO Hexadentate 1:1 26.6 
MECAM Hexadentate 1:1 29.1 
Enterobactin Hexadentate 1:1 35.5 
pFe3+ values taken from references 29 and 56. 
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Figure 6 
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Figure 9 (part)
(A) 
(B) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
31 
 
 
 
0.00
0.05
0.10
0.15
0.20
0.25
400 500 600 700 800
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
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Graphical abstract 
 
 
     Synopsis 
The hydrazone chelators pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde 
isonicotinoyl hydrazone (SIH) bind both iron(II) and iron(III) with high affinity. The tridentate 
ligands completely encompass the coordinated iron which renders it inaccessible to other 
potentially reactive molecules, including oxidising agents, reducing agent and complexing 
agents. 
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Highlights 
 Updated value for logβ2(Fe3+) for pyridoxal isonicotinoyl hydrazone (PIH) is 37.0. 
 Updated value for logβ2(Fe3+) for salicylaldehyde isonicotinoyl hydrazone (SIH) is 37.6. 
 Updated pFe3+ values for PIH and SIH are greater than 24. 
 The iron complexes of PIH and SIH are not redox active under biological conditions. 
 Both PIH and SIH bind iron(II) and iron(III) extremely rapidly. 
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